ArticleProceedings of the National Academy of Sciences of the United States of America2012
MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Game of Omes: ribosome profiling expands the MHC-I immunopeptidome.Current opinion in immunology · 2023Review
- MLN4924 Inhibits Defective Ribosomal Product Antigen Presentation Independently of Direct NEDDylation of Protein Antigens.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Direct Conjugation of NEDD8 to the N-Terminus of a Model Protein Can Induce Degradation.Cells · 2021Article
- A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.Nature reviews. Immunology · 2021Review
- Effect of Protein Denaturation and Enzyme Inhibitors on Proteasomal-Mediated Production of Peptides in Human Embryonic Kidney Cells.Biomolecules · 2019Article
- Flu DRiPs in MHC Class I Immunosurveillance.Virologica Sinica · 2019Review
- Inhibition of the Deubiquitinase Usp14 Diminishes Direct MHC Class I Antigen Presentation.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells.The Journal of clinical investigation · 2016Article
- Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.Leukemia · 2016Article
- Enhanced Direct Major Histocompatibility Complex Class I Self-Antigen Presentation Induced by Chlamydia Infection.Infection and immunity · 2016Article
- Ubiquitous Autofragmentation of Fluorescent Proteins Creates Abundant Defective Ribosomal Products (DRiPs) for Immunosurveillance.The Journal of biological chemistry · 2015Article
- Chemical biology strategies for posttranslational control of protein function.Chemistry & biology · 2014Review
- Article
- Re-examining class-I presentation and the DRiP hypothesis.Trends in immunology · 2014Review
- Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.Journal of leukocyte biology · 2014Review
- Effects of Peptide on NK cell-mediated MHC I recognition.Frontiers in immunology · 2014Review
- Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- The E3 ubiquitin ligase UBE3C enhances proteasome processivity by ubiquitinating partially proteolyzed substrates.The Journal of biological chemistry · 2013Article
- Amsterdamming DRiPs.Molecular immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
To better understand the generation of MHC class I-associated peptides, we used a model antigenic protein whose proteasome-mediated degradation is rapidly and reversibly controlled by Shield-1, a cell-permeant drug. When expressed from a stably transfected gene, the efficiency of antigen presentation is ~2%, that is, one cell-surface MHC class I-peptide complex is generated for every 50 folded source proteins degraded upon Shield-1 withdrawal. By contrast, when the same protein is expressed by vaccinia virus, its antigen presentation efficiency is reduced ~10-fold to values similar to those reported for other vaccinia virus-encoded model antigens. Virus infection per se does not modify the efficiency of antigen processing. Rather, the efficiency difference between cellular and virus-encoded antigens is based on whether the antigen is synthesized from transgene- vs. virus-encoded mRNA. Thus, class I antigen-processing machinery can distinguish folded proteins based on the precise details of their synthesis to modulate antigen presentation efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.